ClinicalTrials.gg
RecruitingNCT05698992Updated May 15, 2026

Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer

An observational study in Esophageal Cancer, Esophageal Neoplasms and Gastric Cancer, sponsored by Region Skane. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Region Skane · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Esophageal Neoplasms with a site in Sweden — 8 open to participants now, 8 under way, 1 of them phase 3. Esophageal Neoplasms · Sweden.

Planned enrollment
9th of 11
100 · median 1,000
Started
2023
with 1 other
Observational
11 of 30
4 open now
Registered
26th of 30
by date
Lead sponsor
3 of 30
Region Skane

Among the 30 studies in Esophageal Neoplasms with a site in Sweden, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2023, is one of 11 observational ones, and was the 26th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

8 of the 30 studies in Esophageal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Esophageal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.

Read the detailed description

Sweden has had a National Cancer Rehabilitation Programme since 2014. This emphasises that all people with cancer have the right to individualised rehabilitation and that the contact nurse has an important role to play in identifying needs and ensuring evidence-based interventions throughout the cancer process to promote rehabilitation. The needs for optimised rehabilitation vary according to several parameters such as the person's personal circumstances and preferences, social support and type of cancer disease.

Despite this and a growing number evidence within this area cancer rehabilitation is often not integrated in clinical care. The current cancer care focuses on medical and treatment related interventions. It is a challenge for health services to find models to identify and meet the increased need for cancer rehabilitation in a systematic and structured way throughout the cancer process, based on the specific needs of each individual. This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.

03

Conditions studied

  • Esophageal Cancer
  • Esophageal Neoplasms
  • Gastric Cancer
  • Stomach Neoplasm

Keywords

  • Cancer rehabilitation
  • Recovery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

*patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden (Skåne), and are planned to undergo or has undergone curative surgerytreatment at Skåne University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 18 years of age
  • esophageal or gastric cancer
  • living in Southern Sweden (Skåne)
  • are planned to undergo curative surgerytreatment at Skåne University Hospital.

Exclusion criteria

Exclusion Criteria:

  • unable to communicate in the Swedish language
  • suffering from a cognitive impairment that poses a barrier for participating in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
15 Months
Patient registry
Yes

Groups and cohorts

  • Experimental group

    Patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden, and who are planned to undergo curative surgery treatment at Skåne University Hospital. n=100 (anticipated)

    Other: evidence-based individualized rehabilitation

  • Historical control group

    The historical control group consists of patients, living in Southern Sweden, who underwent esophageal or gastric cancer surgery between 2013 - 2021 at Skåne University Hospital. n=100 (anticipated)

Interventions

  • Otherevidence-based individualized rehabilitation

    The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.

06

What researchers measure

Primary outcomes

  1. General Quality of life

    The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  2. General Quality of life

    The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  3. General Quality of life

    The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  4. General Quality of life

    The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

Secondary outcomes

  1. Esophageal and gastric cancer specific Quality of life

    The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  2. Esophageal and gastric cancer specific Quality of life

    The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  3. Esophageal and gastric cancer specific Quality of life

    The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  4. Esophageal and gastric cancer specific Quality of life

    The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  5. Information needs

    The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  6. Information needs

    The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  7. Information needs

    The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  8. Information needs

    The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

  9. International Physical Activity Questionnaire

    The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  10. International Physical Activity Questionnaire

    The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  11. International Physical Activity Questionnaire

    The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  12. International Physical Activity Questionnaire

    The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  13. Hospital Anxiety and Depression Scale

    HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  14. Hospital Anxiety and Depression Scale

    HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  15. Hospital Anxiety and Depression Scale

    HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  16. Hospital Anxiety and Depression Scale

    HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  17. Assessment of Survivorship Concerns

    ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  18. Assessment of Survivorship Concerns

    ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  19. Assessment of Survivorship Concerns

    ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  20. Assessment of Survivorship Concerns

    ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  21. Resilience

    Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  22. Resilience

    Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  23. Resilience

    Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.

    Time frame: Instrument will be answered by the patientafter surgery at 6 months postoperative

  24. Resilience

    Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  25. Assessment of rehabilitation needs.

    Assessment of rehabilitation needs will be used to measure patients rehabilitation needs. A 4 point Likert scale which ranges from "no problem" to "very troublesome problem" . Higher scores indicate more problems.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  26. Assessment of rehabilitation needs.

    Higher scores indicate more problems.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative

  27. Assessment of rehabilitation needs.

    Higher scores indicate more problems.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative

  28. Assessment of rehabilitation needs.

    Higher scores indicate more problems.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative

  29. Psychological Distress

    Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision)

  30. Psychological Distress

    Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.

  31. Psychological Distress

    Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.

  32. Psychological Distress

    Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

  33. Sickness absence/work

    Sickness abscens and to which extent the patient work will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision).

  34. Sickness absence/work

    Sickness abscens and to which extent the patient work will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.

  35. Sickness absence/work

    Sickness abscens and to which extent the patient work will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.

  36. Sickness absence/work

    Sickness abscens and to which extent the patient work will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

  37. Physical activity

    Single item question concerning amount of hours physical activity per day.

    Time frame: Single item question will be answered by the patient at baseline (at treatment decision).

  38. Physical activity

    Single item question concerning amount of hours physical activity per day.

    Time frame: Single item question will be answered by the patient at approximately 1 week preoperative.

  39. Physical activity

    Single item question concerning amount of hours physical activity per day.

    Time frame: Single item question will be answered by the patient after surgery at 6 months postoperative.

  40. Physical activity

    Single item question concerning amount of hours physical activity per day.

    Time frame: Single item question will be answered by the patient after surgery at 12 months postoperative.

  41. Alcohol use

    Single item questions concerning alcohol use.

    Time frame: Single item questions will be answered by the patient at baseline (at treatment decision).

  42. Alcohol use

    Single item questions concerning alcohol use.

    Time frame: Single item questions will be answered by the patient at approximately 1 week preoperative.

  43. Alcohol use

    Single item questions concerning alcohol use.

    Time frame: Single item questions will be answered by the patient after surgery at 6 months postoperative.

  44. Alcohol use

    Single item questions concerning alcohol use.

    Time frame: Single item questions will be answered by the patient after surgery at 12 months postoperative.

  45. Tobacco use

    Single item questions concerning tobacco use.

    Time frame: Single item questions will be answered by the patient at baseline (at treatment decision).

  46. Tobacco use

    Single item questions concerning tobacco use.

    Time frame: Single item questions will be answered by the patient at approximately 1 week preoperative.

  47. Tobacco use

    Single item questions concerning tobacco use.

    Time frame: Single item questions will be answered by the patient after surgery at 6 months postoperative.

  48. Tobacco use

    Single item questions concerning tobacco use.

    Time frame: Single item questions will be answered by the patient after surgery at 12 months postoperative.

  49. Height

    Single item question concerning height in meters.

    Time frame: Single item question will be answered by the patient at baseline (at treatment decision).

  50. Weight

    Single item question concerning weight in kilograms.

    Time frame: Single item question will be answered by the patient at baseline (at treatment decision).

  51. Weight

    Single item question concerning weight in kilograms.

    Time frame: Single item question will be answered by the patient at approximately 1 week preoperative.

  52. Weight

    Single item question concerning weight in kilograms.

    Time frame: Single item question will be answered by the patient after surgery at 6 months postoperative.

  53. Weight

    Single item question concerning weight in kilograms.

    Time frame: Single item question will be answered by the patient after surgery at 12 months postoperative.

  54. Body Mass Index (BMI)

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Instrument will be answered by the patient after surgery at baseline (at treatment decision).

  55. Body Mass Index (BMI)

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.

  56. Body Mass Index (BMI)

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.

  57. Body Mass Index (BMI)

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

  58. Dysphagia

    Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision).

  59. Dysphagia

    Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.

  60. Dysphagia

    Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.

  61. Dysphagia

    Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

  62. Rehabilitation process

    Questions about the rehabilitation process will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient at baseline (at treatment decision).

  63. Rehabilitation process

    Questions about the rehabilitation process will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.

  64. Rehabilitation process

    Questions about the rehabilitation process will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.

  65. Rehabilitation process

    Questions about the rehabilitation process will be measured by single items concerning this area.

    Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.

Other outcomes

  1. Demographics

    Demographic details will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). There are no scales, only quality registry data.This data includes gender,cancerdiagnosis, tumourstage, comorbidity according to ASA, surgerydate, postoperative tumourstage.

    Time frame: The data will be collected 12 months after surgery.

  2. Overall survival

    Overall survival will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). There are no scales, only quality registry data.

    Time frame: Up to 1 year after surgery

  3. Incidence and severity of general complications

    Incidence rate and severity of general complication according to Clavien-Dindo classification. Genereal complications will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer).

    Time frame: Up to 30 days postoperative

  4. Change of level of care

    Incidence rate of change of level of care in the context of postoperative care will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer).

    Time frame: Up to 30 days postoperative

  5. Length of stay

    Length of stay at the hospital will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). Will be measured in number of days.

    Time frame: from the day before surgery to discharge from the hospital

  6. Rate of re-admission

    The rate of re-admission up to 30 days postoperative will be collected via NREV (Swedish national quality registry for esophageal and gastric cancer).

    Time frame: Up to 30 days postoperative

  7. Discharge destination

    Postoperative discharge destination (i.e if the patients goes home or to another care unit after discharge) will be collected via NREV (Swedish national quality registry for esophageal and gastric cancer)

    Time frame: The data will be collected 12 months postoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 58 months is below that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Jan 26, 2023
StartActual
Feb 27, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698992
Lead sponsor
Region Skane
Responsible party
Marlene Malmström (Associate professor, Region Skane) — Principal investigator
First posted
Jan 26, 2023
Start date
Feb 27, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 15, 2026

Study contacts

Wenche Melander, PhD-student
Contact
wenche.melander@skane.se
+4646171310
Marlene Malmström, PhD
Contact
marlene.malmström@skane.se
+4646175950

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion